By Doug Macron
The University of Massachusetts and the Whitehead Institute for Biomedical Research this week returned fire against the Max Planck Institute and Alnylam Pharmaceuticals in their ongoing legal battle, counterclaiming that, among other things, Max Planck inappropriately sought to replace the Whitehead-appointed law firm overseeing prosecution of the intellectual property at issue in the case.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
